2021 was a challenging year in many ways. It was also a year when AZBio Members stepped up to meet these challenges. As we look forward to 2022, we are focused on AZBio’s vision of Arizona becoming a top-ten bioscience state. We invite you to learn more about how you can get engaged with AZBio in 2022 and participate in focus initiatives designed to move us toward the top-ten. Continue reading
Category Archives: AZBio News
TGen-UArizona Medical School Study Points to Possible new Treatment Options for Breast Cancer Patients
Cxcl10 protein can indicate both positive and negative directions of cancer trajectoryContinue reading
HTG Completes HTP Product Next-Phase Development Milestone
Expands Potential Market and Study Opportunities for HTG Transcriptome Panel
Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19
Dec 22. 2021 – Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Continue reading
TGen Helps Develop Analysis Tool. Leading to More-Accurate evaluation of New Brian Tumor Treatments and Individual Estimates of Survival
‘Nomograms’ accounting for sex differences in the design of clinical trials should help deliver new precision treatments to glioblastoma patientsContinue reading
The MedTech Conference Plans to Return to Boston in 2022 with a Strong In-Person Presence
WASHINGTON, D.C. – The MedTech Conference, powered by the Advanced Medical Technology Association (AdvaMed), announced today it will return to Boston from October 24-26, 2022, with hopes of reconvening the industry after two unconventional years. The annual three-day event provides world-class programming, networking, and business development opportunities for the global medical technology community. The conference will once again offer options for virtual attendance while encouraging safe in-person participation.
Respiratory Tract Bacterial Extracts Could Prevent COVID-19
Researchers from the UArizona College of Medicine – Tucson found that the bacterial lysate OM-85 blocked SARS-CoV-2 infection by decreasing the ability of the coronavirus to bind to the lung cell surface receptor ACE2.Continue reading
HTG Expands Therapeutics Scientific Advisory Board With Addition of Dr. Jerald Radich
Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular GeneticsContinue reading
Mayo Clinic purchases 228-acre land parcel in North Phoenix for further patient care expansion and the development of a biotechnology corridor
PHOENIX — Mayo Clinic has acquired 228 acres of land adjacent to its campus in North Phoenix, securing the ability to expand its patient-centered model of care and paving the way to develop a transformative biotechnology corridor.Continue reading
Scintillation Nanotechnologies, Inc. to exhibit nanoparticle scintillator platform at SLAS 2022 International Conference and Exhibition.
Tucson-based Scintillation Nanotechnologies, Inc. has been selected by the Society for Laboratory Automation and Screening (SLAS) to be included on “Innovation AveNEW” at the society’s upcoming 2022 International Conference and Exhibition. The company – a startup founded to commercialize inventions stemming from research at the University of Arizona – has developed next generation nanoparticles for the detection of radiolabeled compounds directly in aqueous samples, eliminating the need for extensive sample preparation and sample destruction that are experienced with competing products. The unique chemical and physical properties of the company’s aquaSCINTTM and nanoSPATM products give researchers unprecedented insight into drug uptake, binding, and distribution while saving time and reducing costly hazardous waste . Continue reading